MyFinsight
Home
Blog
About
Contact
Download
Download image
Share-based compensation
expense
$104,003K
(-8.87%↓ Y/Y)
Proceeds from exercise of
stock options
$5,545K
(-61.27%↓ Y/Y)
Proceeds from issuance of
common stock under...
$3,350K
(-25.75%↓ Y/Y)
Accrued expenses and
other liabilities
$25,387K
(39.86%↑ Y/Y)
Net income/(loss)
$22,388K
(111.31%↑ Y/Y)
Accounts payable
$18,223K
(1573.37%↑ Y/Y)
Amortization of discounts for
credit facility and...
$2,496K
Depreciation expense
$1,558K
(-13.30%↓ Y/Y)
Net cash provided
by/(used in) operating...
$45,327K
(151.59%↑ Y/Y)
Net cash provided by
financing activities
$8,884K
(-94.05%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$1,250K
(289.68%↑ Y/Y)
Canceled cashflow
$128,728K
Canceled cashflow
$11K
Net increase
(decrease) in cash, cash...
$55,148K
(-8.56%↓ Y/Y)
Canceled cashflow
$313K
Accounts receivable
$101,279K
(73.17%↑ Y/Y)
Inventory
$15,267K
(41.95%↑ Y/Y)
Prepaid and other
current assets
$8,087K
Other assets
$4,061K
(676.03%↑ Y/Y)
Right-of-use assets and lease
liabilities
-$34K
(87.73%↑ Y/Y)
Payments of employee tax
withholding related to...
$11K
(-80.70%↓ Y/Y)
Net cash used in
investing activities
-$313K
(22.33%↑ Y/Y)
Purchase of property and
equipment
$313K
(-22.33%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)